We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01349361
First Posted: May 6, 2011
Last Update Posted: May 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
May 5, 2011
May 6, 2011
May 6, 2011
March 2011
January 2013   (Final data collection date for primary outcome measure)
complete disappearance of the BCC
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.
Not Provided
Interventional
Phase 2
Not Provided
  • Photodynamic Therapy
  • Basal Cell Carcinomas
Procedure: Daylight mediated photodynamic therapy
Experimental: Daylight-PDT
Intervention: Procedure: Daylight mediated photodynamic therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • superficial BCC

Exclusion Criteria:

  • Immunosuppression
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT01349361
2010-024517-31
Not Provided
Not Provided
Not Provided
Hans Christian Wulf, Bispebjerg Hospital
Bispebjerg Hospital
Not Provided
Not Provided
Bispebjerg Hospital
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP